On March 31, 2022 Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, reported that the Board of Directors has approved the Company’s financial statements for 2021 (Press release, Nykode Therapeutics, MAR 31, 2022, View Source [SID1234611277]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"2021 was another year of significant progress for Nykode," said Michael Engsig, Chief Executive Officer of Nykode Therapeutics. "We launched our new company name and brand identity, a first step in our journey to become a leading global immunotherapy company. We signed two transformative research licensing agreements with Adaptive Biotechnologies and Regeneron, which will accelerate the development of our technology platform across multiple areas of high unmet need. In addition, we made substantial progress in the development of our oncology and infectious disease pipelines, including dosing the first subjects in our Phase I/II clinical trial of Nykode’s next-generation SARSCoV-2 vaccine candidates. Furthermore, we expanded and evolved the organization to over 100 employees, adding new valuable skills and capabilities to our team. We believe Nykode is wellpositioned to continue to execute on our world-class collaborations and advance our technology platform and clinical programs, and we look forward to sharing updates this year."
Highlights for 2021
• March-Adopted IFRS (International Financial Reporting Standards) and announced initiative to explore a potential listing of its shares on the Nasdaq Global Market in the US
• March – Nykode’s first IND was opened in the VB10.NEO program
• June-Initiated a Phase I/II trial to evaluate two next-generation SARS-CoV-2 virus DNA vaccine candidates to address emerging variants of concern
• July-Entered into worldwide in-licensing agreement with Adaptive Biotechnologies for clinically validated SARS-CoV-2 T cell epitopes to combine in next-generation T cell vaccine candidate to specifically address emerging SARS-CoV-2 variants of concern
• November-First subject dosed in Phase I/II clinical trial with next-generation SARS-CoV-2 vaccine candidates
• November-Nykode announced a change of company name from Vaccibody to Nykode Therapeutics
• November-Entered into multi-target license and collaboration agreement with Regeneron
• December-Announced first subject dosed with its T cell-focused next-generation SARSCoV-2 vaccine candidate
Full year 2021 key figures
• Total operating income of USD 35.8 million in 2021, compared to USD 215.7 million in 2020
• Total operating expenses of USD 46.5 million in 2021, compared to USD 37.4 million in 2020
• Net loss of USD 9.4 million in 2021, compared to a net profit of USD 149.8 million in 2020
• Cash and cash equivalents of USD 216.2 million at year-end 2021, compared to USD 183.9 million at year-end 2020 • Other current financial assets of USD 12.2 million at year-end 2021, compared to USD 24.9 million at year-end 2020 • Total equity of USD 194.1 million at year-end 2021, compared to USD 178.9 million at yearend 2020
• Total assets of USD 265.6 million at year-end 2021, compared to USD 230.0 million at yearend 2020
—The Company’s annual accounts for the financial year 2021, including the financial statements and annual report, are together with the auditor’s report attached to this announcement. Investors and analysts are invited to join a webcast presentation of the 2021 financial results conducted by CEO Michael Engsig and other members of management April 1, 2022, at 11.30 a.m. CET / 5.30 a.m. ET.
An updated corporate presentation will be available in the Investors section of the Company’s website at 7:00 a.m. CET on April 1 at www.nykode.com/investors. The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website here.